Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

NexgenRX Inc.

Healthcare CA NXG

0.44CAD
0.01(3.53%)

Last update at 2026-06-05T19:46:00Z

Day Range

0.430.44
LowHigh

52 Week Range

0.260.44
LowHigh

Fundamentals

  • Previous Close 0.42
  • Market Cap27.74M
  • Volume99011
  • P/E Ratio39.00
  • Dividend Yield3.85%
  • EBITDA2.46M
  • Revenue TTM17.93M
  • Revenue Per Share TTM0.25
  • Gross Profit TTM 14.93M
  • Diluted EPS TTM0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1.94M 1.03M -0.30506M 0.13M 2.01M
Minority interest - - - - -
Net income 1.29M 0.61M -0.33197M -0.02240M 4.02M
Selling general administrative 1.57M 1.38M 1.27M 1.27M 6.28M
Selling and marketing expenses - - - - -
Gross profit 14.93M 13.12M 10.82M 10.18M 9.81M
Reconciled depreciation 1.22M 1.27M 1.31M 1.41M 1.33M
Ebit - - - - 2.20M
Ebitda - - - 1.56M 3.40M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 2.23M 1.20M -0.14388M 0.29M 2.20M
Other operating expenses - - - - -
Interest expense 0.03M 0.03M 0.03M 0.02M 0.06M
Tax provision 0.65M 0.41M 0.03M 0.16M -2.00800M
Interest income - - - - -
Net interest income -0.17330M -0.17059M -0.16118M -0.15319M -0.18939M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.16M -2.00800M
Total revenue 17.93M 16.48M 13.85M 12.78M 11.84M
Total operating expenses 15.70M 15.28M 13.99M 12.49M 9.64M
Cost of revenue 3.00M 3.35M 3.03M 2.60M 2.03M
Total other income expense net -0.12397M - - - -
Discontinued operations - - - - -
Net income from continuing ops 1.29M 0.61M -0.33197M -0.02240M 4.02M
Net income applicable to common shares - - - - 3.89M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 36.60M 30.46M 30.20M 25.75M 29.44M
Intangible assets 1.40M 2.33M 3.15M 4.10M 5.12M
Earning assets - - - - -
Other current assets - - - - 17.87M
Total liab 28.98M 22.84M 22.48M 16.90M 19.72M
Total stockholder equity 7.62M 7.62M 7.71M 8.85M 9.71M
Deferred long term liab - - - - -
Other current liab 26.63M 21.80M 20.42M 15.54M 17.91M
Common stock - - - 19.29M 19.29M
Capital stock 5.66M 5.66M 5.47M 20.94M 20.94M
Retained earnings -2.43681M -2.42879M -2.14206M -16.43282M -15.52506M
Other liab - - - - -
Good will 1.08M 1.24M 1.24M 1.24M 1.24M
Other assets - - - - 1.74M
Cash 4.78M 1.71M 1.88M 1.77M 2.32M
Cash and equivalents - - - - -
Total current liabilities 28.69M 22.41M 22.08M 16.51M 19.55M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - 0.84M 0.50M
Total current assets 32.40M 24.65M 23.34M 18.00M 20.83M
Long term investments 0.37M 0.18M - - -
Net tangible assets - - - - 1.71M
Short term investments - - - - -
Net receivables 0.73M 0.82M 0.73M 0.41M 0.48M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.98M 0.50M 1.18M 0.92M 1.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 4.20M 5.81M 6.85M 7.74M 8.60M
Capital lease obligations 0.37M 0.53M 0.46M 0.43M 0.40M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.18440M -0.18064M 0.00000M -0.50661M -1.36963M
Change to liabilities - - - 0.00000M 0.54M
Total cashflows from investing activities - - - - -1.36963M
Net borrowings -0.11056M -0.10227M -0.07923M -0.20822M -0.80932M
Total cash from financing activities -1.40831M -0.82297M -0.91906M -1.10958M -0.93979M
Change to operating activities - - - - 0.01M
Net income 1.29M 0.61M -0.33197M -0.02240M 4.02M
Change in cash 3.07M -0.17110M 0.11M -0.55013M 1.52M
Begin period cash flow 1.71M 1.88M 1.77M 2.32M 0.80M
End period cash flow 4.78M 1.71M 1.88M 1.77M 2.32M
Total cash from operating activities 4.98M 1.15M 1.28M 1.07M 3.82M
Issuance of capital stock 0.00000M 0.19M 0.06M - -
Depreciation 1.22M 1.27M 1.31M 1.41M 1.33M
Other cashflows from investing activities - - - - -
Dividends paid -1.29776M 0.91M 0.90M 0.90M 0.13M
Change to inventory - - - - -
Change to account receivables 0.10M -0.09717M -0.31684M 0.07M -0.12425M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - -
Change to netincome - - - - -1.95371M
Capital expenditures 0.35M 0.32M 0.25M 0.39M 0.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.67M -1.13984M 0.23M -0.58153M 0.43M
Stock based compensation 0.00501M 0.02M 0.04M 0.06M 0.10M
Other non cash items 0.03M 0.03M 0.03M -0.19633M -0.03456M
Free cash flow 4.63M 0.83M 1.03M 0.56M 2.45M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NXG
NexgenRX Inc.		 0.01 3.53% 0.44 39.00 32.68 1.55 4.64 1.39 7.84
NURS
Hydreight Technologies Inc		 -0.165 3.50% 4.55 406.00 25.91 7.85 20.38 7.45 109.02
RHT
Reliq Health Technologies Inc		 - -% 0.21 - - 3.19 5.12 4.07 -10.7759
ADK
Diagnos Inc		 -0.01 4.44% 0.21 - 10.00 411.24 18.74 389.06 -6.1551
PTEC
Principal Technologies Inc		 -0.18 40.91% 0.26 - - 62.75 355.42 72.08 -0.8075

Reports Covered

Stock Research & News

View All

Profile

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.

NexgenRX Inc.

191 The West Mall, Toronto, ON, Canada, M9C 5K8

Key Executives

Name Title Year Born
Mr. Ronald C. Loucks B.B.A. Founder, CEO, Pres & Director 1950
Mr. Kelly Elher C.A., CPA, CA, CPA Chief Financial Officer NA
Mr. Andrew Munroe Sr. VP of Pharma & Payor Partners NA
Mr. Jason Robinson Sr. VP of Admin. NA
Ms. Doreen Harvey Lead HR NA
Mr. Paul Anthony Bolger LL.B., M.B.A. Company Sec. NA
Mr. Avik Debroy Financial Controller NA
Mr. Ronald C. Loucks B.B.A. Founder, CEO, President & Director 1950
Mr. Andrew Munroe Vice President of Operations NA
Mr. Jason Robinson Vice President of Administration NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.